S. Johnston

985 total citations
17 papers, 783 citations indexed

About

S. Johnston is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, S. Johnston has authored 17 papers receiving a total of 783 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in S. Johnston's work include Cancer Treatment and Pharmacology (13 papers), HER2/EGFR in Cancer Research (5 papers) and Advanced Breast Cancer Therapies (4 papers). S. Johnston is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), HER2/EGFR in Cancer Research (5 papers) and Advanced Breast Cancer Therapies (4 papers). S. Johnston collaborates with scholars based in United Kingdom, United States and Belgium. S. Johnston's co-authors include G. Walsh, H. J. Illiger, Nathalie Bardy‐Bouxin, Christian Dittrich, Valerijus Ostapenko, Marc Salzberg, K. Mross, Fátima Cardoso, Markus Borner and Dirk Behringer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

S. Johnston

16 papers receiving 767 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Johnston United Kingdom 9 433 341 332 231 108 17 783
JFR Robertson United Kingdom 12 435 1.0× 327 1.0× 333 1.0× 146 0.6× 184 1.7× 13 830
Kimberly B. Koenig United States 12 510 1.2× 245 0.7× 475 1.4× 203 0.9× 146 1.4× 15 855
Alessandra Balduzzi Italy 18 710 1.6× 247 0.7× 626 1.9× 169 0.7× 172 1.6× 35 1.0k
Aiko Sueta Japan 18 340 0.8× 455 1.3× 487 1.5× 185 0.8× 104 1.0× 45 947
M. Piccart Belgium 13 681 1.6× 154 0.5× 409 1.2× 163 0.7× 90 0.8× 38 889
Mutsuko Yamamoto‐Ibusuki Japan 20 445 1.0× 553 1.6× 509 1.5× 250 1.1× 80 0.7× 45 1.1k
Eleanor Gutteridge United Kingdom 8 553 1.3× 214 0.6× 200 0.6× 268 1.2× 61 0.6× 27 800
Atsushi Shimomura Japan 21 513 1.2× 439 1.3× 595 1.8× 213 0.9× 204 1.9× 48 1.1k
Graham H.P. Richmond United Kingdom 5 473 1.1× 492 1.4× 175 0.5× 321 1.4× 63 0.6× 6 947
Per-Olof Malmström Sweden 6 501 1.2× 621 1.8× 323 1.0× 254 1.1× 74 0.7× 6 1.0k

Countries citing papers authored by S. Johnston

Since Specialization
Citations

This map shows the geographic impact of S. Johnston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Johnston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Johnston more than expected).

Fields of papers citing papers by S. Johnston

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Johnston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Johnston. The network helps show where S. Johnston may publish in the future.

Co-authorship network of co-authors of S. Johnston

This figure shows the co-authorship network connecting the top 25 collaborators of S. Johnston. A scholar is included among the top collaborators of S. Johnston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Johnston. S. Johnston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Jm, Murphy, et al.. (2023). Medication adherence in older adults receiving systemic treatment for cancer.. Journal of Geriatric Oncology. 14(8). S65–S66. 1 indexed citations
2.
Okines, Alicia, Kabir Mohammed, Alistair Ring, et al.. (2022). Vinorelbine After Prior Treatment With Eribulin for Advanced Breast Cancer: A Single-Centre Experience Suggesting Cross-Resistance. Clinical Breast Cancer. 22(7). e825–e831. 3 indexed citations
3.
4.
Fribbens, Charlotte, Isaac García-Murillas, Matthew Beaney, et al.. (2017). Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Annals of Oncology. 29(1). 145–153. 118 indexed citations
5.
Dolly, Saoirse, Amna Sheri, Marina Parton, et al.. (2010). Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer?. Oncology. 79(5-6). 331–336. 8 indexed citations
6.
Brunetto, André T., Debashis Sarker, Dionysis Papadatos-Pastos, et al.. (2010). A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. British Journal of Cancer. 103(5). 607–612. 8 indexed citations
7.
Ashley, S., et al.. (2010). Moderate dose capecitabine in older patients with metastatic breast cancer: A standard option for first line treatment?. The Breast. 19(5). 377–381. 9 indexed citations
8.
Johnston, S., et al.. (2009). Correlation of tumor burden, liver and bone metastasis with serum extracellular domain HER2 expression in front-line metastatic breast cancer.. Cancer Research. 69(2_Supplement). 3146–3146. 1 indexed citations
9.
Tutt, Andrew, Cheryl Gillett, Sarah E. Pinder, et al.. (2009). Microtubule Associated Protein Tau Expression as a Predictive and Prognostic Marker in a Trial Assessing Sequential Docetaxel as Adjuvant Chemotherapy for Early Breast Cancer (TACT).. Cancer Research. 69(24_Supplement). 607–607. 2 indexed citations
10.
Zembryki, Denise, Henry Gómez, María Koehler, et al.. (2009). Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl). 1095–1095. 5 indexed citations
11.
Banerji, Udai, S. Ashley, Geraldine Walsh, et al.. (2007). Factors determining outcome after third line chemotherapy for metastatic breast cancer. The Breast. 16(4). 359–366. 20 indexed citations
12.
Johnston, S., Peter Barrett‐Lee, Anthony Howell, et al.. (2006). TEXAS (Taxotere® EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC. Cancer Chemotherapy and Pharmacology. 59(3). 413–418. 5 indexed citations
13.
Banerji, Udai, G. Walsh, S. Ashley, et al.. (2006). A study of factors determining outcome of patients receiving third line chemotherapy for metastatic breast cancer: The Royal Marsden Hospital experience. Journal of Clinical Oncology. 24(18_suppl). 657–657. 1 indexed citations
14.
Chan, Stephen, M. E. Scheulen, S. Johnston, et al.. (2005). Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology. 23(23). 5314–5322. 386 indexed citations
15.
Johnston, S.. (2004). Fulvestrant and the sequential endocrine cascade for advanced breast cancer. British Journal of Cancer. 90(S1). S15–S18. 35 indexed citations
16.
Eisen, Tim, Ian E. Smith, S. Johnston, et al.. (1998). Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.. Journal of Clinical Oncology. 16(4). 1350–1357. 27 indexed citations
17.
Smith, IE, G. Walsh, Alison Jones, et al.. (1995). High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.. Journal of Clinical Oncology. 13(2). 424–429. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by JFR Robertson Breakdown of academic impact, for papers by Kimberly B. Koenig Breakdown of academic impact, for papers by Alessandra Balduzzi Breakdown of academic impact, for papers by Aiko Sueta Breakdown of academic impact, for papers by M. Piccart Breakdown of academic impact, for papers by Mutsuko Yamamoto‐Ibusuki Breakdown of academic impact, for papers by Eleanor Gutteridge Breakdown of academic impact, for papers by Atsushi Shimomura Breakdown of academic impact, for papers by Graham H.P. Richmond Breakdown of academic impact, for papers by Per-Olof Malmström
Rankless by CCL
2026